학술논문
Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR)
Document Type
Article
Author
Source
In: Radiotherapy and Oncology . (Radiotherapy and Oncology, July 2024, 196)
Subject
Language
English
ISSN
18790887
01678140
01678140